Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country
Dahiwadkar currently heads four technology companies- WipeOut Inc, Cognota Healthcare Technologies, IT Shastra India and Moringa Techsolv, which he has founded
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
FDA changes inspection classification of the facility to Voluntary Action Indicated
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
Subscribe To Our Newsletter & Stay Updated
